 For patients that have had a complete resection and treatment with adjuvant chemoradiation, and for patients with locally advanced nonresectable disease treated with standard chemoradiation, there is presently no therapy available to decrease the chance of disease reoccurrence. Our hypothesis is that immunization with a modified CEA peptide in MontanideGM-CSF can lead to expansion of CEA-reactive CTL and result in control of CEA expressing pancreatic carcinomas. 